drugset / Trial / NCT03012477

CISPLATIN + AZD-1775 In Breast Cancer

NCT03012477

Phase 2 Completed 34 enrolled Dana-Farber Cancer Institute AstraZeneca · collab
NaSingle-groupOpen-labelTreatment

Summary

This research study is studying a combination of drugs as a possible treatment for triple-negative breast cancer that has spread to other areas of the body. The names of the study interventions involved in this study are: * Cisplatin * AZD1775

Timeline

Start
2017-01-18
Primary completion
2019-05-07
Completion
2020-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Adavosertib Small molecule 200 mg Oral
Subject Cisplatin Other / unclassified 75 mg/m2 Intravenous